Skip to content

Advertisement

  • Original article
  • Open Access

Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance

†Contributed equally
Cancer Communications201838:19

https://doi.org/10.1186/s40880-018-0284-1

©  The Author(s) 2018

  • Received: 26 October 2017
  • Accepted: 8 March 2018
  • Published:

Abstract

Background

Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusions show dramatic responses to specific tyrosine kinase inhibitors (TKIs); however, after 10–12 months, secondary mutations arise that confer resistance. We generated a murine xenograft model using patient-derived NSCLC cells isolated from the pleural fluid of two patients with NSCLC to investigate the mechanisms of resistance against the ALK- and EGFR-targeted TKIs crizotinib and osimertinib, respectively.

Methods

Genotypes of patient biopsies and xenograft tumors were determined by whole exome sequencing (WES), and patients and xenograft-bearing mice received targeted treatment (crizotinib or osimertinib) accordingly. Xenograft mice were also treated for prolonged periods to identify whether the development of drug resistance and/or treatment responses were associated with tumor size. Finally, the pathology of patients biopsies and xenograft tumors were compared histologically.

Results

The histological characteristics and chemotherapy responses of xenograft tumors were similar to the actual patients. WES showed that the genotypes of the xenograft and patient tumors were similar (an echinoderm microtubule-associated protein-like 4-ALK (EML4–ALK) gene fusion (patient/xenograft: CTC15035EML4–ALK) and EGFR L858R and T790M mutations (patient/xenograft: CTC15063EGFR L858R, T790M)). After continuous crizotinib or osimertinib treatment, WES data suggested that acquired ALK E1210K mutation conferred crizotinib resistance in the CTC15035EML4–ALK xenograft, while decreased frequencies of EGFR L858R and T790M mutations plus the appearance of v-RAF murine sarcoma viral oncogene homolog B (BRAF) G7V mutations and phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha (PIK3C2A) A86fs frame shift mutations led to osimertinib resistance in the CTC15063EGFR L858R, T790M xenografts.

Conclusions

We successfully developed a new method of generating drug resistance xenograft models from liquid biopsies using microfluidic technology, which might be a useful tool to investigate the mechanisms of drug resistance in NSCLC.

Keywords

  • Drug resistance
  • Target treatment
  • Lung cancer
  • Pleural effusion
  • Patient-derived xenografts

Background

Lung cancer is highly prevalent and a leading cause of cancer-related mortality worldwide [1] and in China [2]. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all new lung cancer cases [3]. Interestingly, the mortality rates of lung cancer differ significantly among developed countries [4].

EGFR mutations occur in up to 50% of all East Asian lung adenocarcinoma patients, while a genetic rearrangement resulting in the fusion of the 5′ region of EML4 to the 3′ region of ALK occurs in 2%–5% of NSCLC patients [5, 6]. EML4–ALK fusions are most prevalent among young adenocarcinoma patients who are light or never smokers [5, 6]. Additionally, single exon 19 deletions have been described in lung adenocarcinoma [7].

Initially, first-generation TKIs such as gefitinib (for EGFR-positive NSCLC) and crizotinib (for EML4–ALK fusion-positive NSCLC) demonstrate strong anti-tumor activity; however, most patients develop resistance and subsequently relapse. In EML4–ALK fusion-positive NSCLC patients, resistance results from further mutations in ALK, with the L1196M mutation predominating [8]. The third-generation ALK TKI, lorlatinib is effective against L1196M mutant ALK, but leads to another resistance mutation, L1198F, which in turn results in a re-sensitization to crizotinib [9, 10]. Reductions in the efficacy of the EGFR TKI gefitinib are most often caused by secondary mutations in EGFR, approximately 50% of which are T790M mutations, which most often occur within 9–14 months of EGFR-TKI treatment [11].

The third-generation EGFR TKI osimertinib is effective for treating EGFR T790M mutant NSCLC patients with advanced disease [12], but resistance still occurs, resulting in secondary relapse [13, 14]. Previous studies have shown that the response of patient-derived xenografts to EGFR or ALK TKIs closely approximates the clinical outcomes observed in the donors’ responses to similar TKI treatments [15–17]. Thus, xenografts are useful tools to investigate mechanisms of NSCLC drug resistance, for which it is difficult to get second or third patient-derived biopsies. Ideally, NSCLC patients should undergo secondary biopsies of their primary tumors or metastases to characterize their specific drug resistance profiles. However, the implementation of secondary biopsies is often limited by the location of the lesion or metastases, patient willingness to undergo additional invasive procedures, and other factors, all of which confound efforts to improve the clinical outcomes of targeted therapy. Approximately 50% of NSCLC patients develop malignant pleural effusion. Minimally invasive drainage of accumulated pleural effusion can, therefore, reduce chest discomfort while providing pleural fluid specimens for secondary biopsy and xenograft modeling.

In this study we used a murine patient-derived xenograft model with NSCLC cells isolated from the pleural fluid of two NSCLC patients under crizotinib and osimertinib treatments, to evaluate the development of resistance mechanisms.

Patients and methods

Patients

Our study was approved by the Institutional Review Board of Shanghai Chest Hospital (Ethical Approval Number KS1513; 2015), and written informed consent was obtained from all patients prior to participation in our study. Patients were chosen according to the following criteria: advanced NSCLC patients with mutations, rearrangements or gene fusions and malignant pleural effusion. Pleural fluid samples were obtained from two patients (patients CTC1503EML4–ALK and CTC15063EGFR L858R, T790M) who were diagnosed with NSCLC with malignant pleural effusion and underwent treatment at our institution.

Establishment of xenograft models and in vivo drug treatments

Malignant tumor cells were isolated from the pleural fluid of patients using the ClearCell FX1 system (Clearbridge BioMedics Pte Ltd, Singapore) according to the manufacturer’s protocol. Tumor cells were subcutaneously inoculated into both flanks of 6–8-week-old female CB17-SCID mice (Vital River Laboratory Animal Technology Co Ltd, Beijing, China), with six mice per group. Tumors were measured twice weekly with a caliper, and tumor volumes were calculated using the formula: volume = (length × width2)/2. Tumors generated from malignant tumor cells isolated from patients CTC15035EML4–ALK and CTC15063EGFR L858R, T790M using this method are subsequently referred to as the CTC15035EML4–ALK and CTC15063EGFR L858R, T790M xenograft models, respectively.

In long-term experiments, crizotinib (114 days) and osimertinib (95 days) treatments were continued until resistance was detected based on TGI < 100% and T/C > 0 in at least one of six mice. Tumors from these resistant mice (osimertinib mouse number 3 (osimertinib-3) and crizotinib mouse number 6 (crizotinib-6) were then inoculated in the right flanks of six immune-deficient nu/nu mice (Vital River Laboratory Animal Technology Co Ltd) for further measurements (Fig. 1).
Fig. 1
Fig. 1

Flow chart of this study

When tumors reached 100–300 mm3, the mice were randomly divided into three groups, with six mice of similar average tumor volume in each group. Vehicle (0.5% hydroxypropyl methylcellulose and 0.5% Tween-80) was administered orally to the control group once per day. Mice with CTC15035EML4–ALK or crizotinib-6 tumors received 50 mg/kg crizotinib (SelleckChem, Houston, TX, USA) orally once per day, while mice with CTC15063EGFR L858R, T790M or osimertinib-3 tumors received 50 mg/kg erlotinib (SelleckChem) or 5 mg/kg osimertinib (SelleckChem) orally once per day.

Tumor sizes were used to calculate T/C values, which served as indicators of anti-tumor efficacy: T/C = (Tti − Tt0)/(Vci − Vc0). Tumor volumes were also used to calculate tumor growth inhibition (TGI) rates according to the following formula: TGI (%) = [1 − (Tti − Tt0)/(Vci − Vc0)] × 100, where Tti indicates tumor volume of the treatment group, Tt0 indicates tumor volume of the treatment group on the first day of treatment, Vci indicates tumor volume of vehicle control group, and Vc0 indicates tumor volume of the vehicle group on the first day of treatment.

Histology

Biopsy samples of tumor tissues and xenografts from patients CTC15035EML4–ALK and CTC15063EGFR L858R, T790M were fixed in 10% buffered formalin within 30 min after resection/collection. Tissues were then subjected to routine hematoxylin and eosin (H&E) staining, and NSCLC diagnoses were confirmed by a qualified pathologist.

Whole exome sequencing (WES)

Genomic DNA from tumors and xenografts was fragmented and hybridized using the SureSelect Human All Exome kit (version 5, Agilent Technologies, Santa Clara, CA, USA). Exome sequences were enriched based on the consensus coding sequence (CCDS) data base (https://www.ncbi.nlm.nih.gov/CCDS/) using the SureSelect software (Illumina, San Diego, CA, USA), and the shotgun libraries were sequenced with a paired-end read length of 2 × 150 bases on the HiSeq Xten platform (Illumina) using the CAVSAVR, version 1.8, software (Illumina) with default parameters. Adapter sequences were removed to obtain high-quality reads. Contaminating mouse sequences in the xenograft data were removed using our proprietary bioinformatics program (xenograft tool) to improve the sensitivity and specificity of variation detection. All xenograft reads were first mapped to the murine genome using the Burrows–Wheeler Aligner with 18K-mer parameters. Using the xenograft tool, reads that aligned to murine genomic sequences were mapped with 80K-mer parameters to a set of human and mouse homologous genome regions that was constructed based on human–mouse sequence alignments of BLASTZ results. BLASTZ, an independent implementation of the Gapped BLAST algorithm was specifically designed for aligning two entire mammalian genomes [18].

The high-quality reads from resected patient samples and the xenograft reads remaining after xenograft tool filtering were aligned to the NCBI human reference genome (hg19) using Burrows–Wheeler Aligner software to identify single-nucleotide variants (SNVs).

Identification of mutations in drug-resistant xenograft tumors

Localized insertion/deletion (InDel) mutations were analyzed with reads in FASTQ format using the Genome Analysis Toolkit (GATK), version 3.5 (https://software.broadinstitute.org/gatk/). Regions that required realignment were identified using the GATK Realigner Target Creator. For SNV detection, the MuTect algorithm was used to identify candidate SNVs in xenografts that exhibited drug resistance based on comparison to control xenografts from the same patient. The ANNOVAR software (http://annovar.openbioinformatics.org/en/latest/) was used for SNV annotation. The possible effects of nonsynonymous mutations on the encoded proteins were predicted using the dbNSFP database, version 3.1 (http://varianttools.sourceforge.net/Annotation/DbNSFP), by collating outputs from the SIFT32 and Polyphen2 prediction programs. Candidate somatic resistance InDels were identified using InDelocator (http://www.broadinstitute.org/cancer/cga/indelocator) based on comparisons to control xenografts from the same patient. Candidate InDels were only considered when they were supported by ≥ 5 reads and when the ratio of the number of supporting reads to the maximum breakpoint read depth was > 0.05. All InDel calls were manually reviewed using the Integrative Genomics Viewer (http://software.broadinstitute.org/software/igv/) before being annotated with ANNOVAR. Transcripts from gene fusions were identified according to the Ion Torrent AmpliSeq RNA Fusion Lung Cancer Research Panel protocol (Thermo Fisher Scientific, Waltham, MA, USA), which simultaneously sequences 70 different fusion transcripts and analyzes 5′ and 3′ ALK expression. The Ion Reporter software (Thermo Fisher Scientific) was used to detect gene fusion events, indicate fusion partners, and determine fusion junctions.

Confirmation of mutations by Sanger sequencing

Genomic DNA sequences containing the somatic mutations of drug-resistant xenograft were amplified by touchdown PCR using primers that targeted the variant sequences with thermal cycling performed at 98 °C for 10 min; 94 °C for 2 min; 10 cycles of 94 °C for 10 s, 75–50 °C for 70 s (reduced 2.5 °C every cycle), 72 °C for 45 s; 20 cycles of 94 °C for 15 s, 50 °C for 30 s, 74 °C for 45 s; and finally 72 °C for 150 s. Sizes of the amplified fragments were confirmed by agarose gel electrophoresis, and the fragments were purified using Agencourt Ampure XP beads (Beckman Coulter, Brea, CA, USA).

Gene functional annotation

Functional annotation was performed using the DAVID Bioinformatics Resources, version 6.8 (https://david.ncifcrf.gov/content.jsp). The interrogating dataset contained the mutated genes, and the background dataset consisted of all genes in the human genome. Genes annotated in the Kyoto Encyclopedia of Genes and Genomes (KEGG; http://www.kegg.jp/) or Gene Ontology (GO; http://www.geneontology.org/) databases as functioning in signaling pathways, biological processes, or molecular functions were subjected to Fisher’s exact test. Enrichment was considered statistically significant at P < 0.05.

Results

Morphology and pathology of resected patient and xenograft tumors

Patient CTC15035EML4–ALK

CTC15035EML4–ALK tumor cells were obtained from a 47-year-old female patient (patient CTC15035EML4–ALK) who presented with stage IV lung adenocarcinoma with pleura, retroperitoneal lymph node, and brain metastases (Fig. 2a). She was initially treated with two cycles of gemcitabine plus carboplatin. However, disease progression occurred with malignant pleural effusion and mass enlargement (Fig. 2b), at which point pleural fluid was collected to generate the CTC15035EML4–ALK xenograft tumors. A tumor biopsy sample collected from the patient was ALK fusion-positive and crizotinib was subsequently applied [19, 20], which stabilized the patient’s disease for 18 months (Fig. 2c). Prior to crizotinib treatment, the histological characteristics of the tumor biopsy (Fig. 2d) were highly similar to the xenograft tumors (Fig. 2e).
Fig. 2
Fig. 2

Computed tomography (CT) scans and pathology for patient CTC15035EML4–ALK with stage IV bronchogenic carcinoma and the patient-derived xenograft tumors. a Baseline CT chest scan on 2014-11-14 showed there was a nodule in the middle lobe of the right lung and a small amount pleural effusion in the lower lobe of the right lung. b After two gemcitabine plus carboplatin chemotherapy cycles, CT of disease progression on 2014-12-23 showed the pleural effusion increased significantly compared with that of baseline. c After 2 months of crizotinib targeted therapy, CT chest scan on 2015-3-12 showed the disease was stable and the pleural effusion decreased compared with that of pre-crizotinib treatment. Pathology was examined by H&E staining of the tumor biopsy from d patient CTC15035EML4–ALK when pleural effusion increased significantly and, e a xenograft tumor from CTC15035EML4–ALK. Histology of xenograft tumors was well-matched with those of primary tumors

Patient CTC15063EGFR L858R, T790M

CTC15063EGFR L858R, T790M tumor cells were obtained from a 52-year-old male NSCLC patient (patient CTC15063EGFR L858R, T790M), who had previously presented with stage IV lung cancer with pleura, peritoneum, and right lung metastases. The patient underwent surgical tumor resection and adjuvant chemotherapy with navelbine plus cisplatin. At a follow-up visit approximately 4.5 years later, disease recurrence with right pleura metastasis was found (Fig. 3a). A tumor biopsy specimen tested positive for the EGFR L858R mutation, so the patient was treated with erlotinib. A partial response was achieved, but disease progression with malignant pleural effusion occurred 26 months after beginning erlotinib (Fig. 3b). Pleural fluid was then collected, and malignant cells isolated from the pleural fluid were used to generate the CTC15063EGFR L858R, T790M xenografts. Subsequently, another biopsy sample of the tumor tested positive for EGFR L858R and T790M mutations, so the patient was treated with osimertinib, and his disease was stabilized for 13 months (Fig. 3c). Histological characteristics of the CTC15063EGFR L858R, T790M tumor xenografts were highly similar to the tumor biopsy (Fig. 3d, e).
Fig. 3
Fig. 3

Computed tomography (CT) scans and pathology for patient CTC15063EGFR L858R, T790M and the patient-derived xenograft tumors. CT chest scans of patient CTC15063EGFR L858R, T790M were recorded 4.5 years after undergoing surgical resection and subsequent adjuvant chemotherapy (navelbine plus cisplatin). a Disease recurrence was found in a CT scan as a right sub-pleural nodule on 2012-3-12; b disease progression 26 months after erlotinib treatment was visible in a CT scan as malignant pleural effusion on 2014-6-27; c CT reexamination after 2 months of osimertinib treatment showed stable disease on 2015-10-8. Pathology (H&E staining) of tumor biopsy from d patient CTC15063EGFR L858R, T790M and e a xenograft CTC15063EGFR L858R, T790M tumor after osimertinib treatment

The development of crizotinib resistance in EML4–ALK NSCLC and xenografts was related to an E1210K mutation in the ribose-binding pocket of ALK

Patient CTC15035EML4–ALK and mice with the tumors derived from CTC15035EML4–ALK were treated with crizotinib. The effects of crizotinib treatment on xenograft tumor sizes are presented in Fig. 4a. On day 21, the mean xenograft tumor volume of the CTC15035EML4–ALK control group grew from 176.65 ± 24.77 to 1764.72 ± 34.43 mm3, whereas under 50 mg/kg crizotinib treatment the xenograft tumors shrank from 176.18 ± 20.00 to 128.26 ± 34.43 mm3 (P < 0.001), with a TGI% of 103.2% and a T/C% of − 3.02% on day 21 (Fig. 4a).
Fig. 4
Fig. 4

The effect of crizotinib on CTC15035EML4–ALK xenografts and their development of crizotinib resistance. a CTC15035EML4–ALK xenograft growth curves for female nu/nu mice (mean ± SEM, n = 6) treated with 50 mg/kg crizotinib or vehicle control for 21 days. b CTC15035EML4–ALK xenograft growth curves in six female nu/nu mice (crizotinib 1–6) for 114 days with 50 mg/kg crizotinib (mean ± SEM, n = 6). c Secondary CTC15035EML4–ALK xenografts derived from crizotinib-6 under 50 mg/kg crizotinib or vehicle control treatments (mean ± SEM, n = 6). d Fusion transcripts of EML4 Exon 18 to ALK Exon 20, which occurred in the tumor biopsy from patient CTC15035EML4–ALK and the CTC15035EML4–ALK xenografts, were identified by RNA amplification sequencing with an ultra-deep sequencing depth of approximately 50,000-fold of the EML4–ALK fusion locus; e the novel acquired ALK E1210K mutation in crizotinib-6 xenografts at a frequency of 9% (d, e are displayed with Integrative Genomics Viewer)

On day 114 of crizotinib treatment, the tumor in the crizotinib-6 mouse had grown to 892.98 mm3, which was significantly larger than tumors in the other mice in the crizotinib treatment group (Fig. 4b). To further evaluate the crizotinib-6 tumor, we generated new xenografts by implanting fragments of the crizotinib-6 tumor into the flanks of naive nu/nu mice. These secondary xenografts were treated with 50 mg/kg crizotinib once per day or vehicle control for 21 days (Fig. 4c). The control group tumors grew from 278.15 ± 31.52 to 1954.75 ± 347.77 mm3, whereas under 50 mg/kg crizotinib treatment, the xenograft tumors grew from 273.86 ± 36.55 to 432.29 ± 71.20 mm3 (P < 0.001), with a TGI% of 90.55% and a T/C% of 9.45% on day 21. Unlike the previous experiment in which all CTC15035EML4–ALK tumors shrank following crizotinib treatment, these secondary crizotinib-6 tumors exhibited a slow rate of growth despite crizotinib treatment (Fig. 4c), indicating acquired resistance had been achieved.

Genomic DNA from tumor tissues of patient CTC15035EML4–ALK and those of crizotinib-6 were subjected to WES. These deep sequencing results are summarized in Additional file 1: Table S1, and the genetic variations identified in the samples are summarized in Table 1. The transcript fusion of EML4 exon 18 to ALK exon 20 was identified in both the patient’s tumor and crizotinib-6 xenografts (Fig. 4d). A novel acquired ALK mutation, E1210K, which mapped to the ribose-binding pocket of ALK, was also identified in crizotinib-6 at a frequency of 9% (Fig. 4e). Although the E1210K mutation has not been biochemically characterized, a previous study reported that the E1210K mutation conferred crizotinib resistance in vitro [21].
Table 1

Whole exome sequencing of patients-derived biopsies and xenografts

Sample

Yield (Gbases)

Reads (× 106)

% ≥ Q30 bases (PF)

Key mutations

Biopsy from patient CTC15035EML4–ALK

13.63

90.88

90.73

EML4–ALK fusion (EML4 exon18–ALK exon 20)

Crizotinib-6 xenograft

27.77

185.10

91.38

EML4–ALK fusion (EML4 exon18–ALK exon 20); ALK: E1210K (9%)

Biopsy from patient CTC15063EGFR L858R, T790M

14.72

98.15

90.94

EGFR: L858R (85.7%) and T790M (71.5%)

Xenograft from patient CTC15063EGFR L858R, T790M

25.09

167.24

90.04

EGFR: L858R (83.3%) and T790M (77.6%)

Osimertinib-3 xenograft

27.38

182.52

90.73

EGFR: L858R (53.6%) and T790M (41.7%); PIK3C2A: R86fs (11%); BRAF: G7V (11.5%)

Gbases gigabases, M million, PF post filter, EML4–ALK echinoderm microtubule-associated protein-like 4–anaplastic lymphoma kinase, EGFR epidermal growth factor receptor

The development of osimertinib resistance in EGFR L858R, T790M NSCLC and xenografts was related to secondary mutations in BRAF and PIK3C2A combined with reduced EGFR-T790M mutations

Mice with tumors derived from CTC15063EGFR L858R, T790M were treated with erlotinib to confirm the partial response previously observed in the patient. Volumes of CTC15063EGFR L858R, T790M xenografts were not reduced by erlotinib treatment. The mean size of control xenografts on days 0 and 35 were 164.82 ± 16.68 and 337.7 ± 52.15 mm3, respectively, and for 5 mg/kg-treated tumors they were 273.35 ± 43.94 mm3 on day 35 vs. 164.37 ± 17.21 mm3 on day 0 (P < 0.001), with a TGI% of 36.96% and a T/C% of 63.04% (Fig. 5a). Patient CTC15063EGFR L858R, T790M and the mice with xenograft tumors derived from him were treated with osimertinib. The effects of osimertinib treatment on xenograft tumor volumes are presented in Fig. 5b. On day 21, the mean tumor volume for the control group was significantly greater than that of the osimertinib treatment group (282.59 ± 22.02 mm3 vs. 34.15 ± 4.27 mm3, TGI% = 174.98%, T/C% = − 74.98% (P < 0.001), whereas they were not different at day 0 (139.88 ± 9.40 mm3 vs. 141.15 ± 11.9 mm3), demonstrating a significant initial anti-tumor response. Osimertinib treatment was continued, and the osimertinib-3 tumor reached 445.16 mm3 on day 95 (Fig. 5c).
Fig. 5
Fig. 5

The effect of osimertinib on CTC15063EGFR L858R, T790M xenografts tumor inhibition or tumor re-development due to osimertinib resistance. a CTC15063EGFR L858R, T790M xenograft growth curves for female nu/nu mice (mean ± SEM, n = 6) treated with 50 mg/kg erlotinib or vehicle control for 35 days. b CTC15063EGFR L858R, T790M xenograft growth curves for female nu/nu mice (mean ± SEM, n = 6) treated with 5 mg/kg osimertinib or vehicle for 24 days. c CTC15063EGFR L858R, T790M xenograft growth curves of six female nu/nu mice (osimertinib 1–6) treated with 5 mg/kg osimertinib for 95 days. d Secondary CTC15063EGFR L858R xenografts derived from osimertinib-3 under 5 mg/kg osimertinib or vehicle control treatments for 21 days (mean ± SEM, n = 6). e Frequencies of the EGFR L858R and T790M mutations in the tumor biopsy from patient CTC15063EGFR L858R, T790M (85.6% and 71.6%, respectively) were similar to those in the initial CTC15063EGFR L858R, T790M xenograft tumors (83.3% and 77.6%, respectively), but were higher than those in osimertinib-3-derived secondary xenografts (53.6% and 41.7%, respectively); f 33 novel secondary mutations were identified in osimertinib-3-derived xenografts, including BRAF (G7V) (11.54%) and PIK3C2A (A86fs) (13.64%)

To further evaluate the osimertinib-3 tumor, we generated new xenografts in naive nu/nu mice using fragments from the osimertinib-3 tumor. These secondary xenografts were treated with 5 mg/kg osimertinib once per day or vehicle control for 21 days (Fig. 5d). The initial xenograft sizes were 220.73 ± 25.60 and 220.65 ± 25.51 mm3 for control and osimertinib-treated mice, respectively. After 21 days, the tumors grew to 372.39 ± 40.18 and 265.41 ± 37.97 mm3 (P < 0.001), respectively, with a TGI% of 70.49% and a T/C% of 29.51% for the osimertinib-treated xenografts (Fig. 5d). Unlike the previous experiment in which all CTC15063EGFR L858R, T790M tumors shrank following osimertinib treatment, these secondary osimertinib-3 tumors exhibited a slow rate of growth despite osimertinib treatment, indicating the achievement of acquired resistance. WES showed that the tumor from patient CTC15063EGFR L858R, T790M, the osimertinib-sensitive CTC15063EGFR L858R, T790M xenograft tumors, and the osimertinib-resistant osimertinib-3 tumor had the EGFR mutations, L858R and T790M. As shown in Table 1, the frequencies of the L858R and T790M mutations in osimertinib-3 (53.6% and 41.7%, respectively) were lower (P = 0.0029 vs. L858R, and P < 0.0001 vs. T790M) than those in the osimertinib-sensitive CTC15063EGFR L858R, T790M xenografts (83.3% and 77.6%, respectively) or from patient-derived CTC15063EGFR L858R, T790M tissue (85.6% and 71.4%, respectively; Fig. 5e). Novel secondary mutations in BRAF (G7V) and PIK3C2A (A86fs) were found only in osimertinib-3 xenografts, occurring at rates of 11.54% and 13.64%, respectively (Fig. 5f; Table 1). Previous studies have shown that genetic variants of BRAF and PIK3C2A are associated with clinical outcome in NSCLC patients [22–24]. Therefore, our results suggested that osimertinib resistance had been acquired through a combination of secondary mutations in BRAF and PIK3C2A and reduced frequency of the EGFR L858R and T790M mutations.

Discussion

The histological characteristics, genotypes, and chemotherapy responses of our patient-derived xenograft tumors were similar to those of the patients’ primary tumor samples. The tumor from patient CTC15035EML4–ALK and the CTC15035EML4–ALK xenografts generated from it contained the EML4–ALK gene fusion, and the tumor from patient CTC15063EGFR L858R, T790M and the CTC15063EGFR L858R, T790M xenografts generated from it contained the EGFR mutations, L858R and T790M. These results validate the use of xenograft tumors to investigate the molecular basis of TKI resistance in NSCLC.

ALK is a transmembrane receptor tyrosine kinase of the insulin receptor superfamily [25]. Various chromosomal rearrangements result in ALK fusions with oncogenic activity in NSCLC, with nearly 20 different ALK-fusion proteins described in the literature, including EML4–ALK, the most common ALK fusion in NSCLC [26]. Downstream signaling from ALK fusion proteins involve the Janus kinase/signal transducer and activator of transcription (JAK/STAT) cell survival pathway and the mitogen-activated protein kinases/extracellular signal-regulated kinases (MEK/ERK) cell proliferation pathway. EML4–ALK fusions occur in approximately 2%–5% of NSCLC cases, the majority of which are adenocarcinomas [5, 6]. Mutations within the ALK tyrosine kinase domain and amplification of ALK fusions contribute to relapse in approximately 33% of NSCLC cases undergoing TKI treatment [21, 27]. Certain SNVs in ALK occur in response to ALK-TKI treatment, including L1196M for crizotinib, G1202R and compound ALK mutations for ceritinib, and G1202R for alectinib [28–30]. A previous study showed that ALK E1210K conferred resistance to crizotinib in vitro [21], and our whole exome sequencing analysis revealed that the ALK E1210K mutation occurred in the crizotinib-resistant xenograft tumor, crizotinib-6. However, the E1210K mutation rate crizotinib-6 was relatively low (9%), which likely contributed to the partial sensitivity of crizotinib-6 to crizotinib, which was reflected by the slow rate of tumor growth in the treatment group (Fig. 4c).

Approximately 70% of NSCLC patients have tumors with EGFR mutations that are sensitive to EGFR-targeted TKIs that inhibit downstream signaling events by binding to the intracellular domain of EGFR [31–33]. Approximately 50% of patients with EGFR-positive tumors acquire resistance to the first- or second-generation TKIs, erlotinib, gefitinib and afatinib, through a number of mechanisms, including secondary mutations in EGFR, such as T790M, C797S, and L792F/Y/H and the activation of alternative signaling pathways, including hepatocyte growth factor (HGF), hepatocyte growth factor receptor (HGFR), human epidermal growth factor receptor 2 (HER2), AXL receptor tyrosine kinase (AXL), Hedgehog (Hh), insulin-like growth factor 1 receptor (IGF-1R)-mediated signaling, or perturbations in downstream proteins, such as protein kinase b (AKT) and phosphatase and tensin homolog (PTEN) signaling; additionally, inhibition of EGFR-TKI-mediated apoptosis by Bcl-2-like protein 11 (BIM) deletions have also been reported [13, 34–37]. Therefore, despite the initial benefits of these first-line TKI treatments [38–40], approximately 50% of NSCLC patients will develop resistance 9–14 months after beginning treatment [38, 41–43]. The second-generation TKIs, afatinib and dacomitinib, have demonstrated limited efficacy for mitigating secondary mutation-induced TKI resistance [44–46]. The third-generation TKI, osimertinib, irreversibly inhibits the tyrosine kinase activity induced by activating EGFR mutations and T790M-mediated resistance mutations without adversely affecting wild-type EGFR [47, 48].

We sought to clarify the mechanisms of acquired resistance to third-generation EGFR-TKIs by inducing resistance in the CTC15063EGFR L858R, T790M xenografts through continuous osimertinib treatment. Neither C797S nor L792F/Y/H mutations were induced in these CTC15063EGFR L858R, T790M xenograft tumors. Amplification of relevant genes, including AKT1, Kirsten rat sarcoma (KRAS), and proto-oncogene tyrosine-protein kinase Yes (YES1), were detected (data not shown) but were not enriched in the osimertinib-resistant xenograft tumor, osimertinib-3. The allele frequencies of L858R and T790M in tumor tissues from patient CTC15063EGFR L858R, T790M and the osimertinib-sensitive CTC15063EGFR L858R, T790M xenograft tumor were similar, whereas the frequencies of these mutations were significantly lower in the osimertinib-resistant xenograft tumor clone, osimertinib-3 (Table 1). These results suggested that a decrease in the L858R and T790M mutation rates contributed to acquired osimertinib resistance in osimertinib-3.

Novel secondary mutations in BRAF (G7V) and PIK3C2A (A86fs) only occurred in osimertinib-3 (Fig. 5f). Mutations in BRAF occur in approximately 3% of NSCLC cases [49]. A recent study by Ichihara et al. [50] showed that Src family kinases are involved in sustaining MAPK signaling in EGFR-TKI-sensitive lung cancer cells treated with osimertinib, and that mutations in PIK3C2A and phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta (PIK3CB) attenuated the anti-tumor effects of osimertinib in T790M-positive lung cancer tumors. Ichihara et al. [50] also found that combined Src family kinase inhibitor plus osimertinib treatment was effective at inhibiting the growth of osimertinib-resistant lung cancer [50]. BRAF and ERK2 are components of the MAPK pathway [51, 52]. Together, the occurrence of BRAF and PIK3C2A mutations in the osimertinib-resistant xenograft tumor and the findings of Ichihara et al. [50] suggest that under continuous EGFR-TKI treatment, MAPK signaling independently contributes to tumor cell proliferation and survival through a mechanism downstream of EGFR, which overrides the effect of EGFR-TKI treatment.

Finally, Src-mediated MAPK signaling mitigates the anti-tumor activity of osimertinib in EGFR-TKI-sensitive lung cancer, and PIK3C2A mutations attenuate the effects of osimertinib in T790M-positive lung cancer. Our findings suggest that under continuous EGFR-TKI treatment, MAPK signaling might also contribute to TKI resistance in ALK fusion-positive NSCLC via an ERK2-mediated mechanism.

One potential shortcoming of our experimental approach was that we did not obtain additional secondary biopsies from either patient when they eventually developed resistance to crizotinib or osimertinib. These samples would have provided further information regarding the mechanisms of drug resistance in NSCLC patients. Additionally, a larger cohort study will be required to assess associations with drug responses in the future.

Conclusions

Using novel microfluidic technology, we successfully developed a new method of generating drug-resistant xenograft models from liquid biopsies. Such drug-resistant xenograft models are feasible tools to understand the mechanisms of NSCLC drug resistance.

Notes

Abbreviations

AKT1: 

RAC-alpha serine/threonine-protein kinase

AXL: 

AXL receptor tyrosine kinase

BCL2: 

B-cell lymphoma-2

BIM: 

Bcl-2-like protein 11

BRAF: 

v-Raf murine sarcoma viral oncogene homolog B

BWA: 

Burrows–Wheeler Aligner

EML4–ALK: 

echinoderm microtubule-associated protein-like 4–ALK

GATK: 

Genome Analysis Toolkit

GF-1R: 

insulin-like growth factor 1 receptor

GO: 

Gene Ontology

HER2: 

human epidermal growth factor receptor 2

HGF: 

hepatocyte growth factor

Hh: 

Hedgehog

H&E: 

hematoxylin and eosin

JAK/STAT: 

Janus kinase/signal transducer and activator of transcription

KEGG: 

Kyoto Encyclopedia of Genes and Genomes

KRAS: 

Kirsten rat sarcoma

MAPK: 

mitogen-activated protein kinase

MEK/ERK: 

mitogen-activated protein kinases, extracellular signal-regulated kinases

NSCLC: 

non-small-cell lung cancer

PCR: 

polymerase chain reaction

PIK3C2A: 

phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha

PTEN: 

phosphatase and tensin homolog

Qd: 

one time per day

SFK: 

Src family kinase

SNV: 

single-nucleotide variant

TGI: 

tumor growth inhibition

TKI: 

tyrosine kinase inhibitor

YES1: 

tyrosine-protein kinase Yes

Declarations

Authors’ contributions

YX, SL and DW conceived and designed the study. YX, FZ, GW, LZ and JZ performed data acquisition and analysis; furthermore, YX and FZ performed statistical analyses. YX, FZ, GW, SL and DW drafted the manuscript; YX, FZ, XP, GW, SL and DW revised and commented on the draft. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to thank GenomiCare Biotechnology (Shanghai) Co., Ltd. for their assistance technology supports.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

None.

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article.

Ethics approval and consent to participate

Our study was performed in accordance with the Declaration of Helsinki regarding ethical principles for research involving human tissues. The protocols for our study were approved by the Institutional Review Board of Shanghai Chest Hospital (Ethical Approval Number KS1513; 2015), and written informed consent was obtained from all patients prior to participation in our study.

Funding

This work was supported by grants from the Science and Technology Commission of Shanghai Municipality (STCSM) (14140902800 and 16140902800), the National Key R&D Program of China (2016YFC1303300), the National Natural Science Foundation of China (81672272), and the Key Project of Shanghai Health & Family Planning Commission (201540365).

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 Huaihai West Road, Shanghai, 200030, China
(2)
Shanghai LIDE Biotech Co., Ltd, 887 Zuchongzhi Rd, Pudong, Shanghai, 201203, China
(3)
GenomiCare Biotechnology (Shanghai) Co., Ltd., Shanghai, 200233, China
(4)
Department of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, China

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. https://doi.org/10.3322/caac.21262.View ArticlePubMedGoogle Scholar
  2. Zheng R, Zeng H, Zhang S, Chen W. Estimates of cancer incidence and mortality in China, 2013. Chin J Cancer. 2017;36:66. https://doi.org/10.1186/s40880-017-0234-3.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917. https://doi.org/10.1002/ijc.25516.View ArticlePubMedGoogle Scholar
  4. Dubey AK, Gupta U, Jain S. Epidemiology of lung cancer and approaches for its prediction: a systematic review and analysis. Chin J Cancer. 2016;35:71. https://doi.org/10.1186/s40880-016-0135-x.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4–ALK. J Clin Oncol. 2009;27:4247–53. https://doi.org/10.1200/JCO.2009.22.6993.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Camidge DR, Kono SA, Flacco A, Tan AC, Doebele RC, Zhou Q, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res. 2010;16:5581–90. https://doi.org/10.1158/1078-0432.CCR-10-0851.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Yu JY, Yu SF, Wang SH, Bai H, Zhao J, An TT, et al. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21. Chin J Cancer. 2016;35:30. https://doi.org/10.1186/s40880-016-0086-2.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4–ALK. Proc Natl Acad Sci USA. 2011;108:7535–40. https://doi.org/10.1073/pnas.1019559108.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Bergqvist S, Brooun A, et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med. 2016;374:54–61. https://doi.org/10.1056/NEJMoa1508887.View ArticlePubMedGoogle Scholar
  10. Kay M, Dehghanian F. Exploring the crizotinib resistance mechanism of NSCLC with the L1196M mutation using molecular dynamics simulation. J Mol Model. 2017;23:323. https://doi.org/10.1007/s00894-017-3495-5.View ArticlePubMedGoogle Scholar
  11. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26. https://doi.org/10.1126/scitranslmed.3002003.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046–61. https://doi.org/10.1158/2159-8290.CD-14-0337.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Morgillo F, Della Corte CM, Fasano M, Ciardiello F. Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open. 2016;1:e000060. https://doi.org/10.1136/esmoopen-2016-000060.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Eberlein CA, Stetson D, Markovets AA, Al-Kadhimi KJ, Lai Z, Fisher PR, et al. Acquired resistance to mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models. Cancer Res. 2015;75:2489.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Stewart EL, Mascaux C, Pham NA, Sakashita S, Sykes J, Kim L, et al. Clinical utility of patient-derived xenografts to determine biomarkers of prognosis and map resistance pathways in EGFR-mutant lung adenocarcinoma. J Clin Oncol. 2015;33:2472–80. https://doi.org/10.1200/JCO.2014.60.1492.View ArticlePubMedGoogle Scholar
  16. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9:338–50. https://doi.org/10.1038/nrclinonc.2012.61.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Yamazaki S, Vicini P, Shen Z, Zou HY, Lee J, Li Q, et al. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models. J Pharmacol Exp Ther. 2012;340:549–57. https://doi.org/10.1124/jpet.111.188870.View ArticlePubMedGoogle Scholar
  18. Schwartz S, Kent WJ, Smit A, Zhang Z, Baertsch R, Hardison RC, et al. Human–mouse alignments with BLASTZ. Genome Res. 2003;13:103–7. https://doi.org/10.1101/gr.809403.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol. 2015;33:1881–8. https://doi.org/10.1200/JCO.2014.59.0539.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–77. https://doi.org/10.1056/NEJMoa1408440.View ArticlePubMedGoogle Scholar
  21. Zhang S, Wang F, Keats J, Zhu X, Ning Y, Wardwell SD, et al. Crizotinib-resistant mutants of EML4–ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des. 2011;78:999–1005. https://doi.org/10.1111/j.1747-0285.2011.01239.x.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Marchetti A, Felicioni L, Malatesta S, Grazia SM, Guetti L, Chella A, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29:3574.View ArticlePubMedGoogle Scholar
  23. Sullivan I, Salazar J, Arqueros C, Andrés M, Sebio A, Majem M, et al. KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer. Clin Transl Oncol. 2017;19:884–90.View ArticlePubMedGoogle Scholar
  24. Tissot C, Couraud S, Tanguy R, Bringuier P, Girard N, Souquet P. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations. Lung Cancer. 2016;91:23–8.View ArticlePubMedGoogle Scholar
  25. Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J. 2009;420:345–61. https://doi.org/10.1042/BJ20090387.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–6. https://doi.org/10.1038/nature05945.View ArticlePubMedGoogle Scholar
  27. Mologni L, Ceccon M, Pirola A, Chiriano G, Piazza R, Scapozza L, et al. NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922. Oncotarget. 2015;6:5720–34. https://doi.org/10.18632/oncotarget.3122.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012;18:1472.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res. 2015;21:2227.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Tchekmedyian N, Ali SM, Miller VA, Haura EB. Acquired ALK L1152R mutation confers resistance to ceritinib and predicts response to alectinib. J Thorac Oncol. 2016;11:e87.View ArticlePubMedGoogle Scholar
  31. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129.View ArticlePubMedGoogle Scholar
  32. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (New York, NY). 2004;304:1497.View ArticleGoogle Scholar
  33. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba I, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339.View ArticlePubMedGoogle Scholar
  34. Chen K, Zhou F, Shen W, Jiang T, Wu X, Tong X, et al. Novel mutations on EGFR Leu792 potentially correlate to acquired resistance to osimertinib in advanced NSCLC. J Thorac Oncol. 2017;12:e65–8. https://doi.org/10.1016/j.jtho.2016.12.024.View ArticlePubMedGoogle Scholar
  35. Yu H, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of mechanisms of acquired resistance to EGFR TKI therapy in 155 patients with EGFR-mutant Lung Cancers. Clin Cancer Res. 2013;19:2240–7.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372:1689.View ArticlePubMedGoogle Scholar
  37. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (New York, NY). 2007;316:1039.View ArticleGoogle Scholar
  38. Gao G, Ren S, Li A, Xu J, Xu Q, Su C, et al. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from six phase III randomized controlled trials. Int J Cancer. 2012;131:E822–9. https://doi.org/10.1002/ijc.27396.View ArticlePubMedGoogle Scholar
  39. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–8. https://doi.org/10.1016/S1470-2045(09)70364-X.View ArticlePubMedGoogle Scholar
  40. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46. https://doi.org/10.1016/S1470-2045(11)70393-X.View ArticlePubMedGoogle Scholar
  41. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–8. https://doi.org/10.1056/NEJMoa0909530.View ArticlePubMedGoogle Scholar
  42. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735–42. https://doi.org/10.1016/S1470-2045(11)70184-X.View ArticlePubMedGoogle Scholar
  43. Ke EE, Wu YL. EGFR as a pharmacological target in EGFR-mutant non-small-cell lung cancer: where do we stand now? Trends Pharmacol Sci. 2016;37:887–903. https://doi.org/10.1016/j.tips.2016.09.003.View ArticlePubMedGoogle Scholar
  44. Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012;13:528–38. https://doi.org/10.1016/S1470-2045(12)70087-6.View ArticlePubMedGoogle Scholar
  45. Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327–34. https://doi.org/10.1200/JCO.2012.44.2806.View ArticlePubMedGoogle Scholar
  46. Ellis PM, Shepherd FA, Millward M, Perrone F, Seymour L, Liu G, et al. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2014;15:1379–88. https://doi.org/10.1016/S1470-2045(14)70472-3.View ArticlePubMedGoogle Scholar
  47. Yap TA, Popat S. Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. Pharmgenomics Pers Med. 2014;7:285–95. https://doi.org/10.2147/PGPM.S55339.PubMedPubMed CentralGoogle Scholar
  48. Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature. 2009;462:1070–4. https://doi.org/10.1038/nature08622.View ArticlePubMedPubMed CentralGoogle Scholar
  49. Chen D, Zhang LQ, Huang JF, Liu K, Chuai ZR, Yang Z, et al. BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS ONE. 2014;9:e101354. https://doi.org/10.1371/journal.pone.0101354.View ArticlePubMedPubMed CentralGoogle Scholar
  50. Ichihara E, Westover D, Meador CB, Yan Y, Bauer JA, Lu P, et al. SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer. Cancer Res. 2017;77:2990–3000. https://doi.org/10.1158/0008-5472.CAN-16-2300.View ArticlePubMedGoogle Scholar
  51. Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghlul S, et al. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res. 2007;67:4933.View ArticlePubMedGoogle Scholar
  52. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s) 2018

Advertisement

Cancer Communications

ISSN: 2523-3548

Contact us